NVCR — NovoCure Ltd

—
Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1645113 · Jersey
Last close
$11.14
Market Cap
$1.30B
52W High
$21.45
52W Low
$9.82
ADV30
1,884,938
Next earnings
2026-10-29

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 193,399,000 148,870,000 -6,171,000 -10,435,000 828,708,000 96,734,000 478,095,000
Jun 2026 183,584,000 142,478,000 -10,562,000 -15,658,000 795,191,000 93,701,000 457,099,000
Mar 2026 174,055,000 135,126,000 -67,420,000 -71,138,000 787,926,000 87,527,000 457,209,000
Dec 2025 174,350,000 132,193,000 -40,393,000 -24,499,000 804,326,000 93,548,000 463,860,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-2,815,000
Investing CF
$409,131,000
Financing CF
$-454,595,000
CapEx
$-22,619,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.30
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,377,153,000
Inventory
$42,224,000
Receivables
$145,821,000
ST Investments
$346,858,000
EBIT TTM
$-119,809,000
Pretax Income TTM
$-152,686,000
Interest Exp TTM
—
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$725,388,032
EBITDA
$-105,790,000
Free Cash Flow
$-89,941,376
Enterprise Value
$1,305,519,872
Total Cash
$463,479,008
Total Debt
$231,554,000
Shares Out
116,915,959
Trailing EPS
$-1.06
Book Value
$3.00
ROE
-35.2%
ROA
-6.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 655,353,000 -153,800,000 -136,227,000 804,326,000 463,860,000 340,466,000 -49,031,000
Dec 2024 605,220,000 -170,496,000 -168,627,000 1,240,784,000 880,605,000 360,179,000 -26,369,000
Dec 2023 509,338,000 -232,870,000 -207,043,000 1,146,129,000 783,633,000 362,496,000 -73,336,000
Dec 2022 537,840,000 -89,523,000 -92,534,000 1,191,648,000 750,478,000 441,170,000 30,788,000

TTM Snapshot

Revenues TTM
$699,193,000
NetIncome TTM
$-148,565,000
OpCashFlow TTM
—
Assets (Latest)
$795,191,000
Forward EPS
$-0.78

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $16.00 · spot: $10.73 · call volume: 53 · put volume: 48
Expected Move to 2027-01-15: ±$15.75 (146.78%) — implied range $-5.02 – $26.48 · ATM straddle on $11.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
PRCT PROCEPT BioRobotics Corp $1.37B $23.78 —
CDRE Cadre Holdings, Inc. $1.39B $32.41 —
BFLY Butterfly Network, Inc. $1.41B $5.75 —
TNDM TANDEM DIABETES CARE INC $1.19B $17.06 —
CNMD CONMED Corp $1.44B $48.39 —

News headlines (Yahoo Finance, 1h cache)

JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields for Pancreatic Cancer
2026-11-13 16:30 · Yahoo
NovoCure (NVCR) Stock May Trade At A Discount Despite FDA Setback
2026-11-12 23:26 · Yahoo
FDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.
2026-11-10 19:10 · Yahoo
Novocure denied FDA approval for metastatic cancer treatment
2026-11-09 16:40 · Yahoo
Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer
2026-11-09 12:00 · Yahoo
Don't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the Stock
2026-11-02 13:15 · Yahoo
NovoCure: 3 Key Takeaways for Long-Term Investors
2026-11-02 02:43 · Yahoo
NovoCure (NVCR) Q3 Results Spark Margin Turn Debate
2026-10-31 08:12 · Yahoo
NovoCure Q3 Earnings Call Highlights
2026-10-29 20:14 · Yahoo
NovoCure (NVCR) Q3 2026 Earnings Call Transcript
2026-10-29 18:43 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.